ESR1 and cancer: Recent research has introduced methods such as EPRIM 124, which evaluates the pre-efficacy of anti-ER therapy based on epigenetic modifications, and WASp, a potential drug targeting epigenetic pathways to prevent transcription-associated DNA damage in malignant tumors by addressing epigenetic deregulation, such as clearing the R-loop.